# CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

- Link: https://www.thailand-business-news.com/pr-news/csl-and-alentis-announce-global-partnership-to-develop-and-commercialise-lixudebart-for-rare-kidney-and-liver-diseases
- Published: 2026-10-05T04:46:00+07:00
- Author: PR Newswire

_Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial
milestones, with global profits shared_

MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ — CSL and
Alentis Therapeutics today announced they have entered into an exclusive global 
collaboration agreement to co-develop and co-promote lixudebart, which has the potential
to become a first-in-class therapy targeting claudin-1 across a range of kidney,
liver and other diseases.

Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients
with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly
progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening
autoimmune disease that can cause irreversible kidney damage and end-stage renal
disease.

With a novel mechanism of action, lixudebart exerts potent anti-inflammatory and
anti-fibrotic effects to potentially prevent and reverse organ damage in ANCA-associated
vasculitis (AAV) and numerous other kidney, liver and lung diseases. The ongoing
phase 2 trial is designed to translate these mechanistic effects into meaningful
clinical impact.  

The collaboration brings together Alentis’ scientific expertise as the leading clinical-
stage biopharmaceutical company targeting claudin-1 and CSL’s global development
and commercialisation capabilities in nephrology, with a shared goal of bringing
innovative and highly impactful treatment options to patients with rare kidney and
liver diseases. In addition to AAV-RPGN, the two companies will advance lixudebart
as a novel treatment for focal segmental glomerulosclerosis (FSGS), a rare progressive
kidney disease, and for primary sclerosing cholangitis (PSC), an autoimmune chronic
liver disease.

"This partnership enables us to dramatically accelerate the development of lixudebart
in several indications in parallel," said Dr Mark Pruzanski, Chief Executive Officer
of Alentis Therapeutics. "We are convinced CSL’s demonstrated clinical development
and commercialisation capabilities in AAV and kidney diseases makes them the right
partner to bring lixudebart to patients. More broadly, this furthers the validation
of claudin-1 as a novel therapeutic target and we are excited about the potential
to accelerate the advancement of our other clinical stage assets and preclinical
pipeline."

"Patients diagnosed with ANCA-associated vasculitis with rapidly progressive glomerulonephritis
face rapid kidney function decline, leaving them at risk of irreversible damage 
even with currently available treatments," said Dr Bill Mezzanotte, EVP, Head of
R&D, CSL. "We believe lixudebart has the potential to become an important new therapeutic
option to help improve kidney function and prevent progression to end-stage kidney
disease, first in AAV-RPGN and hopefully also in focal segmental glomerulosclerosis,
while potentially showing similar benefit on liver function in primary sclerosing
cholangitis. Our partnership with Alentis reflects CSL’s commitment to building 
a leading global nephrology franchise, and our strategic intent to create high-value
external partnerships."

Under the agreement, CSL and Alentis will jointly develop and co-promote lixudebart.
CSL will make an initial payment to Alentis of US$355 million, with Alentis eligible
to receive up to an additional US$1.2 billion in commercial milestone payments. 
In addition to these payments, CSL will fully fund the completion of the ongoing
Phase 2 RENAL trial and planned Phase 3 trial in AAV-RPGN, the Phase 2 trials in
FSGS and PSC and other supporting development activities. Once commercialised, global
profits will be shared 55 per cent to CSL and 45 per cent to Alentis.

**About AAV-RPGNANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis
with rapidly progressive glomerulonephritis (AAV-RPGN) is a rare, severe and potentially
fatal autoimmune disease in which the body’s immune system attacks small blood vessels
in the kidney. RPGN is characterized by rapid loss of kidney function over a very
short period (days to weeks). Despite potent immunosuppressive treatment, most patients
develop significant or total loss of kidney function.

**About LixudebartLixudebart (formerly known as ALE.F02) is an investigational monoclonal
antibody that selectively targets exposed claudin-1, a key driver of inflammatory
and fibrotic signalling pathways in numerous fibrotic diseases of the kidney, liver,
lung, intestine and other solid organs. In an interim analysis of 26 patients with
AAV-RPGN in the ongoing Phase 2 RENAL trial, lixudebart showed promising improvement
in kidney function as assessed by eGFR and proteinuria at 24 weeks. In the Phase
1b FEGATO trial in 41 patients with advanced F3/F4 liver fibrosis, lixudebart demonstrated
improved liver function at 6 weeks. In both studies lixudebart showed dose-dependent
claudin-1 target engagement, along with a favourable safety and tolerability profile.
Lixudebart has been granted Orphan Drug designation by the FDA for the treatment
of Idiopathic Pulmonary Fibrosis (IPF).

**About CSL**
[CSL](http://www.csl.com/) (ASX:CSL; USOTC:CSLLY) is a leading global
biopharma company with a dynamic portfolio of lifesaving medicines, including those
that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and
therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, 
we have been driven by our promise to save lives using the latest technologies. 
Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor–
provides lifesaving products to patients in more than 100 countries and employs 
almost 29,000 people. Our unique combination of commercial strength, R&D focus and
operational excellence enables us to identify, develop and deliver innovations so
our patients can live life to the fullest. For inspiring stories about the promise
of biotechnology, visit [CSL.com/Vita.](http://www.csl.com/vita) For more information
about CSL, visit [CSL.com](http://www.csl.com/).

**About Alentis **
Alentis is a clinical-stage, privately held biotechnology company
pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting
claudin-1 for fibrosis and oncology indications. Beyond the company’s lead antibody
for fibrosis, lixudebart, Alentis is developing oncology candidates ALE.P02 and 
ALE.P03. These are claudin-1 targeted ADCs with a tubulin inhibitor payload and 
topoisomerase‑I inhibitor payload, respectively. ALE.P02 was granted Fast Track 
designation by FDA for the treatment of advanced or metastatic claudin-1 expressing
squamous cancers, irrespective of the organ of origin. Both ADCs are currently in
Phase 1/2 studies enrolling patients with a variety of solid tumor types.

Alentis was founded on the groundbreaking research in the laboratory of Prof. Thomas
Baumert, MD, at the University of Strasbourg and the French National Institute of
Health and Medical Research (Inserm). The company is headquartered in Basel, Switzerland.
Visit [www.alentis.ch](http://www.alentis.ch/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases ](http://www.prnasia.com/story/archive/5063268_AE63268_0?rand=184833)
